youtor.org
TwiceYearly Lenacapavir for PrEP Reduced HIV Infections by 96
>> YOUR LINK HERE: ___ http://youtube.com/watch?v=JWi1bqfmODk
Twice-Yearly Lenacapavir for PrEP Reduced HIV Infections by 96% • The results of an interim analysis from a second pivotal phase 3 clinical trial investigating the use of Gilead’s twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, found that it reduced HIV infections by 96% compared with background HIV incidence (bHIV). • There were two incident cases among 2,180 participants, corresponding to 99.9% of participants not acquiring HIV infection in the lenacapavir group. Twice-yearly lenacapavir also demonstrated superiority to once-daily emtricitabine and tenofovir disoproxil fumarate (F/TDF). • The PURPOSE 2 trial (ClinicalTrials.gov Identifier: NCT04925752), a phase 3, multicenter, randomized double-blind study, is evaluating the safety and efficacy of twice-yearly subcutaneous lenacapavir for PrEP versus once-daily oral F/TDF and bHIV in more than 3,200 cisgender men, transgender men, transgender women and gender non-binary individuals ages 16 years or older who have sex with partners assigned male at birth. There were 88 trial sites in Argentina, Brazil, Mexico, Peru, South Africa, Thailand and the United States. • Thank you for watching the video, wish you health and happiness! • Subscribe to the channel at: https://goo.gl/iz6xA4 • ▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬ • If you have any questions, please contact us by email: [email protected] • Sincerely thank you! • ▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬ • Sign up: / @hivaidsprevention • Facebook: / hivaids2024 • Twitter: / daubenh • Gmail: [email protected]
#############################
